Brain Cells Block an Energy Sensor to Keep Myelin Repair On Track

Myelin, the insulating sheath around neuronal axons, is essential for rapid neural signaling. It is produced by mature oligodendrocytes that differentiate from oligodendrocyte precursor cells (OPCs). When myelin is damaged — as in multiple sclerosis, stroke, viral encephalitis, or aging — OPCs must migrate to the lesion, proliferate, and redifferentiate to repair it. This regenerative capacity is uniquely dependent on the health and responsiveness of OPCs, making their cellular biology a therapeutic priority.

This study set out to understand how different brain cell types respond to glucose fluctuations via the energy-sensing kinase AMPK. When the authors isolated neurons, microglia, astrocytes, OPCs, and mature oligodendrocytes from rat cortices and subjected them to low-glucose conditions, they found a striking exception: OPCs showed no AMPK activation even after 24 hours in glucose-free medium, despite measurable drops in fructose-1,6-bisphosphate (FBP), the glycolytic intermediate that normally triggers the lysosomal AMPK cascade. All other cell types activated AMPK under low-glucose stress.

The mechanistic investigation revealed that in OPCs, the TRPV2 calcium channel — a key step in the lysosomal glucose-sensing pathway — remains active even when glucose and FBP fall. This keeps the v-ATPase proton pump functional and prevents the docking of LKB1 and AMPK at the lysosome. The upstream cause is the acetylation of ALDOC (aldolase C, the dominant aldolase isozyme in OPCs) at lysine-14 (K14). This acetylation prevents ALDOC from sensing FBP depletion and inhibiting TRPV, effectively decoupling OPCs from the standard low-glucose AMPK activation route.

To confirm causality, the researchers engineered a K14R (acetylation-mimicking arginine-to-lysine substitution that blocks acetylation) ALDOC mutant in OPCs. ALDOC-K14R restored AMPK activation in low glucose and severely impaired OPC proliferation and differentiation into mature oligodendrocytes. In three mouse demyelination models — cuprizone, lysophosphatidylcholine (LPC), and experimental autoimmune encephalomyelitis (EAE) — OPC-specific expression of ALDOC-K14R activated AMPK at lesion sites (where glucose is locally low) and disrupted remyelination. Critically, co-deletion of AMPKα1 and AMPKα2 specifically in OPCs rescued remyelination in the ALDOC-K14R mice, confirming the AMPK-dependence of the effect. Pharmacological AMPK activation via the TRPV antagonist AMG-9810, or expression of a constitutively active AMPKγ1 mutant, similarly blocked OPC proliferation and differentiation.

The study establishes that K14 acetylation of ALDOC is a cell-type-specific checkpoint that insulates OPCs from energy-stress signaling during the exact metabolic conditions — low glucose at demyelinated lesions — when robust myelin repair is most needed. This reveals a previously unknown layer of spatiotemporal AMPK regulation in the brain and identifies the ALDOC-K14 acetylation axis as a potential therapeutic target for demyelinating diseases.